Lexaria Bioscience Files 8-K on Shareholder Nominations
Ticker: LEXX · Form: 8-K · Filed: Oct 18, 2024
Sentiment: neutral
Topics: shareholder-nomination, corporate-governance, 8-k
Related Tickers: LXRP
TL;DR
Lexaria Bioscience filed an 8-K regarding shareholder nominations, signaling potential board changes.
AI Summary
Lexaria Bioscience Corp. filed an 8-K on October 18, 2024, reporting shareholder nominations pursuant to Exchange Act Rule 14a-11. The filing date for this report is October 18, 2024, with the earliest event reported on October 16, 2024. The company is incorporated in Nevada and its principal executive offices are located in Kelowna, BC, Canada.
Why It Matters
This filing indicates potential changes or activism within Lexaria Bioscience Corp. related to board composition, which could impact the company's strategic direction.
Risk Assessment
Risk Level: medium — Filings related to shareholder nominations can indicate internal disputes or activist investor involvement, which may lead to uncertainty and volatility.
Key Players & Entities
- Lexaria Bioscience Corp. (company) — Registrant
- October 16, 2024 (date) — Earliest event reported
- October 18, 2024 (date) — Filing date
- Nevada (jurisdiction) — State of incorporation
- Kelowna, BC Canada (location) — Principal executive offices
FAQ
What is the specific purpose of the shareholder nominations mentioned in the 8-K filing?
The filing states that the shareholder nominations are made pursuant to Exchange Act Rule 14a-11, which pertains to the solicitation of proxies for contested elections of directors.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on October 16, 2024.
What is Lexaria Bioscience Corp.'s state of incorporation?
Lexaria Bioscience Corp. is incorporated in Nevada.
Where are Lexaria Bioscience Corp.'s principal executive offices located?
Lexaria Bioscience Corp.'s principal executive offices are located at 100 – 740 McCurdy Road, Kelowna, BC Canada.
What is the filing date of this 8-K report?
This 8-K report was filed on October 18, 2024.
Filing Stats: 506 words · 2 min read · ~2 pages · Grade level 13.5 · Accepted 2024-10-18 16:42:31
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share Warrants to Purchase Common
Filing Documents
- lxrp_8k.htm (8-K) — 24KB
- 0001640334-24-001541.txt ( ) — 160KB
- lxrp-20241016.xsd (EX-101.SCH) — 6KB
- lxrp-20241016_lab.xml (EX-101.LAB) — 16KB
- lxrp-20241016_cal.xml (EX-101.CAL) — 1KB
- lxrp-20241016_pre.xml (EX-101.PRE) — 12KB
- lxrp-20241016_def.xml (EX-101.DEF) — 4KB
- lxrp_8k_htm.xml (XML) — 5KB
08
Item 5.08 Shareholder Director Nominations Further to a recent private placement of share purchase warrants (the "Private Placement Warrants"), as disclosed in a Form 8-K filed on October 16, 2024, the Company is required to seek stockholder approval to such Private Placement Warrants by no later than January 14, 2025. As the date for holding such special meeting is close in time to the anniversary date of the Company's 2024 annual shareholder meeting, it has been determined to hold a joint Annual and Special Meeting of Shareholders on January 14, 2025. Accordingly, any nominating shareholder or shareholder group must submit their notice on Schedule 14N, of their director nominees for the purposes of including such director nominees in the Company's proxy materials to the attention of Vanessa Carle, Head of Legal at vcarle@lexariabioscience.com by no later than noon Eastern Time on Monday, November 25, 2024. 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LEXARIA BIOSCIENCE CORP. /s/ Richard Christopher Richard Christopher CEO, Principal Executive Officer Date: October 18, 2024 3